| Project/Area Number |
26640107
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
斎藤 三郎 東京慈恵会医科大学, 医学部, 教授 (10186934)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 腫瘍免疫 / CTL / リポソーム / 細胞障害性T細胞 / 癌免疫 / 糖鎖構造 / 癌ワクチン / 糖鎖修飾 / アジュバント / 癌抗原 |
|---|
| Outline of Final Research Achievements |
The construction of cDNA library to determine protein antigen that can induce cancer immunity by immunizing with cationic liposome was attempted, but failed to convert into episomal vector which expresses antigen highly efficiently developed for this task. In the analysis using OVA as model cDNA, it was concluded that species-specific sugar chains are necessary for CTL induction with cationic liposome.
So, as a vaccine that induces tumor-selective CTL, a model in which CTL activity is induced by collapse of tumor by suicide gene therapy against MC38 colorectal cancer and 3LL lung cancer cell line was prepared and a model capable of inducing CTL against OVA cDNA was established. At this time, tumor rejection was also confirmed.
|
